Form 4: CEO Patrick Mooney Granted 300,000 SpyGlass Stock Options

SpyGlass Pharma's CEO, Patrick H. Mooney, was granted 300,000 stock options with an exercise price of $16, vesting over four years.

Summary

• Patrick H. Mooney, CEO and Director of SpyGlass Pharma, Inc. (SGP), was granted 300,000 stock options.
• The options have an exercise price of $16 per share.
• The grant date and vesting commencement date is February 5, 2026.
• The options expire on February 5, 2036.
• Vesting occurs over four years: 25% vests on the one-year anniversary of the grant date (February 5, 2027), and 1/48th of the shares vest each month thereafter.
• Vesting is contingent on Mr. Mooney remaining a Service Provider as defined in the Issuer's 2026 Equity Incentive Plan.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a moderately positive development, reflecting standard executive compensation practices aimed at aligning management incentives with long-term shareholder value, without indicating any immediate operational or financial changes.

Positives

• The grant of 300,000 stock options aligns the CEO's incentives with long-term shareholder value creation.
• A 10-year expiration period provides ample time for the company's stock price to appreciate, benefiting the CEO and potentially shareholders.

Negatives

• The exercise price of $16 per share means the stock price must rise above this level for the options to have intrinsic value, indicating a potential hurdle for immediate gains.
• The vesting schedule ties the CEO to the company for four years, which could be seen as a retention mechanism but also limits immediate liquidity for the CEO.

Risks

• The value of the stock options is entirely dependent on the future performance of SpyGlass Pharma, Inc.'s stock price. If the stock price does not exceed the $16 exercise price, the options may expire worthless.
• Vesting is contingent on Mr. Mooney's continued service, meaning forfeiture if employment ceases before full vesting.

Future Outlook

The vesting schedule indicates a forward-looking commitment from the CEO, with 25% of the options vesting on February 5, 2027, and the remainder vesting monthly over the subsequent three years, contingent on continued service.

Management Comments

• The grant is subject to the Reporting Person continuing to be a Service Provider (as defined in the Issuer's 2026 Equity Incentive Plan) through each applicable vesting date.

Industry Context

StockSavvy.ai notes that granting stock options to key executives like the CEO is a standard practice in the biotechnology and pharmaceutical industries, particularly for growth-stage companies. This compensation structure aims to align executive incentives with long-term shareholder value creation by motivating management to increase the company's stock price.

Comparison to Industry Standards

• StockSavvy.ai observes that a 10-year option term and a four-year vesting schedule (one-year cliff followed by monthly vesting) are common structures for executive equity compensation in the U.S. market, particularly within the biotech sector.
• Similar vesting schedules are seen at companies like Moderna (MRNA) or BioNTech (BNTX) for their executive grants, though the specific number of options and exercise price would vary based on company size, stage, and individual executive roles.
• The $16 exercise price would be compared to the company's stock price at the time of grant to assess if it's at-the-money, in-the-money, or out-of-the-money, which is typical for new grants.

Corporate Governance

Related Party Transactions

• The grant of 300,000 stock options to Patrick H. Mooney, the CEO and Director, constitutes a transaction with a related party, disclosed as part of executive compensation.

Stakeholder Impact

• Shareholders: The grant aims to align the CEO's interests with shareholders by incentivizing stock price appreciation. Dilution from future option exercise is a potential long-term consideration.
• Employees: The grant to the CEO may signal confidence in the company's future and could be part of a broader compensation strategy that impacts other employees' equity incentives.

Next Steps

• Continued service of Patrick H. Mooney as a Service Provider to ensure vesting of options.
• Future stock price performance will determine the ultimate value of these options.

Key Dates

Recommendation

This Form 4 filing details a routine executive compensation event (stock option grant) and does not provide new information about the company's operational performance, financial health, or strategic direction that would warrant a change in investment recommendation. It primarily serves to disclose an insider transaction, which is expected for a public company.

Keywords

SpyGlass Pharma, SGP, Stock Options, Executive Compensation, Form 4, Patrick H. Mooney, Equity Incentive Plan, CEO, Director